Aladdin Healthcare Technologies SE reports the sale of software and intellectual property
Aladdin Healthcare Technologies SE reports the sale of software and intellectual property BERLIN/LONDON, 18 May 2021 - Aladdin Healthcare Technologies SE (the "Company") reports that its 100% subsidiary Aladdin Healthcare Technologies Ltd ("Aladdin Ltd") has today completed the sale of specific software and intellectual property to a customer based in the People's Republic of China. As consideration for the sale, the customer has paid GBP 500,000 to Aladdin Ltd.
Aladdin Ltd has developed and is developing various AI-driven technology products for the healthcare market. It has developed prototype AI-driven Drug Discovery Platform and Knowledge Graph which can be tailored to various areas of drug development. The software being sold is the above-described intellectual property but specifically to be used for small molecule drug discovery in the area of Alzheimer's and Dementia. Aladdin retains the rights to use it in other areas.
Contact: Aladdin Healthcare Technologies SE Unter den Linden 10 10117 Berlin Tel 030 7700 140 449 email: email@example.com www.aladdinid.com
18-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Aladdin Healthcare Technologies SE Unter den Linden 10 10117 Berlin
Germany Phone: 030 700140449 E-mail: firstname.lastname@example.org Internet: www.aladdinid.com ISIN: DE000A12ULL2 WKN: A12ULL Listed: Regulated Market in Dusseldorf EQS News ID: 1197804 ? End of Announcement DGAP News Service